• Publications
  • Influence
The soluble isoform of CTLA‐4 as a regulator of T‐cell responses
CTLA‐4 is a crucial immune regulator that mediates both negative costimulation signals to T cells, and regulatory T (Treg)‐cell extrinsic control of effector responses. Here we present evidenceExpand
  • 57
  • 6
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by engaging the immune system. Unfortunately, cures rarely occur and patients display intrinsic or acquiredExpand
  • 69
  • 5
  • PDF
Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.
Following the success of rituximab, 2 other anti-CD20 monoclonal antibodies (mAbs), ofatumumab and obinutuzumab, have entered clinical use. Ofatumumab has enhanced capacity for complement-dependentExpand
  • 48
  • 2
  • PDF
Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?
CTLA-4 is an inhibitory protein that contributes to immune homeostasis and tolerance, a role that has led to its exploitation as a therapeutic in several clinical settings including cancer andExpand
  • 13
  • 2
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies
Summary Anti-CD40 monoclonal antibodies (mAbs) that promote or inhibit receptor function hold promise as therapeutics for cancer and autoimmunity. Rules governing their diverse range of functions,Expand
  • 37
  • 1
Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors
FcγRs are key regulators of the immune response, capable of binding to the Fc portion of IgG Abs and manipulating the behavior of numerous cell types. Through a variety of receptors, isoforms, andExpand
  • 27
  • 1
Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
BackgroundThe inhibitory CTLA-4 molecule is a crucial regulator of immune responses and a target for therapeutic intervention in both autoimmunity and cancer. In particular, CTLA-4 is important inExpand
  • 10
  • 1
Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues
Immune profiling of tissue through multiplex immunohistochemistry is important for the investigation of immune cell dynamics, and it can contribute to disease prognosis and evaluation of treatmentExpand
  • 12
  • 1
Shaving Is an Epiphenomenon of Type I and II Anti-CD20–Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy
Rituximab is an anti-CD20 mAb used in the treatment of B cell malignancies. Loss of surface CD20 Ag from the surface of target cells is thought to be one mechanism governing resistance to rituximab,Expand
  • 5
  • 1
Antibodies to Costimulatory Receptor 4‐1BB Enhance Anti‐tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
&NA; The costimulatory receptor 4‐1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4‐1BB enhance the proliferation and survival of antigen‐stimulated TExpand
  • 44
  • PDF